Advances in anti-obesity therapeutics

Expert Opinion on Investigational Drugs

Volumn 14, Issue 3, 2005, Pages 243-250

  Fong, Tung M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CNS control; Energy balance; Feeding behaviour; Obesity

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; CHOLECYSTOKININ A RECEPTOR; DEXFENFLURAMINE; DOPAMINE TRANSPORTER; FENFLURAMINE; GI 181771; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN 4 RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NALMEFENE; NALOXONE; NALTREXONE; NEUROPEPTIDE Y RECEPTOR; NORADRENALIN TRANSPORTER; OPIATE ANTAGONIST; PHENTERMINE; PLACEBO; RADAFAXINE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SEROTONIN; SEROTONIN 2C AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

ABSORPTION; AUTONOMIC NERVOUS SYSTEM FUNCTION; BRAIN FUNCTION; BRAIN STEM; CLINICAL TRIAL; COGNITION; CONSENSUS; DEVELOPED COUNTRY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; EPIDEMIC; FEEDBACK SYSTEM; FEEDING BEHAVIOR; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; LIFESTYLE; LIPOLYSIS; LIVER TOXICITY; METABOLISM; MITOCHONDRIAL RESPIRATION; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; NUTRIENT; OBESITY; PHYSICAL ACTIVITY; REVIEW; STOMACH EMPTYING; TREATMENT PLANNING; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS; FEEDING BEHAVIOR; HUMANS; LIFE STYLE; OBESITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 17144409447     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.3.243     Document Type: Review

References (81)

1. GLAZER G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch. Intern. Med. (2001) 161 1814-1824.
2. HALPERN A, MANCINI MC: Treatment of obesity: an update on anti-obesity medications. Obes. Rev. (2003) 4:25-42.
3. FARRIGAN C, PANG K: Obesity market overview. Nat. Rev. Drug Discov. (2002) 1:257-258.
4. BARSH GS, SCHWARTZ MW. Genetic approaches to studying energy balance: Perception and integration. Nat. Rev. Genet. (2002) 3 589-600.
5. FRIEDMAN JM: Modern science versus the stigma of obesity. Nat. Med. (2004) 10:563-569.
6. CONE RD, COWLEY MA, BUTLER AA et al.: The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord. (2001) 25(Suppl. 5):S63-S67.
7. SMITH GP: Dopamine and food reward. Prog. Psychobiol. Physiol. Psychol. (1995) 16:83-144.
8. SCHULTZ W. Getting formal with dopamine and reward. Neuron (2002) 36:241-263.
9. SCISLOWSKI PW, TOZZO E, ZHANG Y et al.: Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int. J. Obes. Relat. Metab. Disord. (1999) 23:425-431.
10. GOLDMAN-RAKIC PS,MULYE ECR, WILLIAMS GV: D1 receptors in prefrontal cells and circuits. Brain Res. Rev. (2000) 31 295-301.
11. VAN REE JM, NIESINK RJ, VAN WOLFSWINKEL L et al.: Endogenous opioids and reward. Eur. J. Pharmacol. (2000) 405 89-101.
12. GARDNER EL, VOREL SR: Cannabinoid transmission and reward-related events. Neurobiol. Dis. (1998) 5:502-533.
13. BERRY EM, MECHOULAM R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol. Ther. (2002) 95:185-190.
14. BREIVOGEL CS, CHILDERS SR: The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. (1998) 5:417-431.
15. KISHI T, ASCHKENASI CJ, LEE CE et al.: Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. (2003) 457:213-235.
16. PECKYS D, LANDWEHRMEYER GB: Expression of μ-, κ-, and δ-opioid receptor messenger RNA in the human CNS: a 33P in situ hybridisation study. Neuroscience (1999) 88:1093-1135.
17. WIRTSHAFTER D, DAVID JD: Set points, settling points and the control of body weight. Physiol. Behav. (1977) 19:75-78.
18. BERRIDGE KC: Motivation concepts in behavioral neuroscience. Physiol. Behav. (2004) 81:179-209.
19. BERTHOUD HR: Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev. (2002) 26:393-428.
20. HAGAN MM, RUSHING PA, BENOIT SC, WOODS SC, SEELEY RJ: Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 280:R814-R821.
21. OLSZEWSKI PK, WIRTH MM, GRACE MK, LEVINE AS, GIRAUDO SQ: Evidence of interactions between melanocortin and opioid systems in regulation of feeding. Neuroreport (2001) 12:1727-1730.
22. ALVARO JD, TATRO JB, QUILLAN JM et al.: Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol. Pharmacol. (1996) 50:583-591.
23. DRYDEN S, FRANKISH H, WANG Q, WILLIAMS G: Neuropeptide Y and energy balance: one way ahead for the treatment of obesity? Eur. J. Clin. Invest. (1994) 24:293-308.
24. HEISLER LK, COWLEY MA, TECOTT LH et al.: Activation of central melanocortin pathways by fenfluramine. Science (2002) 297:609-611.
25. WADDEN TA, BERKOWITZ RI, WOMBLE LG et al.: Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes. Res. (2000) 8:431-437.
26. 1) receptors. Psychopharmacology (1997) 132:104-106.
27. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol. (1998) 9:179-181.
28. COLOMBO G, AGABIO R, DIAZ C, et al.: Appetite suppression and weight loss after the cannabinoid antagonist SR-141716. Life Sci. (1998) 63:113-117.
29. VERTY AN, McGREGOR IS, MALLET PE: Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci. Lett. (2004) 354:217-220.
30. PERIO A, BARNOUIN MC, PONCELET M, SOUBRIE P: Activity of SR-141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behav. Pharmacol. (2001) 12:641-645.
31. DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomised controlled trial. JAMA (1999) 281 235-242.
32. JAMES WP, ASTRUP A, FINER N et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2000) 356:2119-2125.
33. BATKAI S, PACHER P, OSEI-HYIAMAN D et al.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 110 1996-2002.
34. RANDALL MD, KENDALL DA, O'SULLIVAN S: The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. (2004) 142:20-26.
35. MENDIZABAL VE, ADLER-GRASCHINSKY E: Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Curr. Vasc. Pharmacol. (2003) 1:301-313.
36. 2 receptors. Am. J. Physiol. Heart Circ. Physiol. (2004) 287(2):H595-H600.
37. SLEEMAN MW, ANDERSON KD, LAMBERT PD, YANCOPOULOS GD, WIEGAND SJ: The ciliary neurotropic factor and its receptor, CNTFR α. Pharm. Acta Helv. (2000) 74:265-272.
38. STAHL N, YANCOPOULOS GD: The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. J. Neurobiol. (1994) 25:1454-1466.
39. GLOAGUEN I, COSTA P, DEMARTIS A et al.: Ciliary neurotropic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. USA (1997) 94 6456-6461.
40. LAMBERT PD, ANDERSON KD, SLEEMAN MW et al.: Ciliary neurotropic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA (2001) 98:4652-4657.
41. MARSH DJ, HOLLOPETER G, HUSZAR D et al.: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet. (1999) 21:119-122.
42. ZIOTOPOULOU M, ERANI DM, HILEMAN SM, BJORBAEK C, MANTZOROS CS: Unlike leptin, ciliary neurotropic factor does not reverse the starvation-induced changes of serum corticosterone and hypothalamic neuropeptide levels but induces expression of hypothalamic inhibitors of leptin signaling. Diabetes (2000) 49:1890-1896.
43. XU B, DUBE MG, KALRA PS et al.: Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology (1998) 139 466-473.
44. ROWLAND NE, MARSHALL M, ROTH JD: Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats. Psychopharmacology (2000) 149:77-83.
45. GEHLERT DR, DRESHFIELD L, TINSLEY F et al.: The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J. Pharmacol. Exp. Ther. (1998) 287:122-127.
46. ANDERSON JW, GREENWAY FL, FUJIOKA K et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. (2002) 10:633-641.
47. RITTER RC, COVASA M, MATSON CA: Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides (1999) 33:387-399.
48. REIDELBERGER RD, HERNANDEZ J, FRITZSCH B, HULCE M: Abdominal vagal mediation of the satiety effects of CCK in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286:R1005-R1012.
49. MATSON CA, RITTER RC: Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am. J. Physiol. (1999) 276:R1038-R1045.
50. BICKEL M, GOSSEL M, GEISEN K et al.: Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int. J. Obes. Relat. Metab. Disord. (2004) 28 211-221.
51. McCALLUM RW, SOYKAN I, SRIDHAR KR et al.: δ-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment. Pharmacol. Ther. (1999) 13:77-80.
52. ISHIGUCHI T, AMANO T, MATSUBAYASHI H et al.: Centrally administered neuropeptide Y delays gastric emptying via Y2 receptors in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281 R1522-R1530.
53. MOLLER DM, KAUFMAN KD: Metabolic syndrome - a clinical and molecular perspective. Ann. Rev. Med. (2005) 56:45-62.
54. FONG TM: Targeting metabolic syndrome. Expert Opin. Investig. Drugs (2004) 13:1203-1206.
55. VAN DER PLOEG LH: Obesity: an epidemic in need of therapeutics. Curr. Opin. Chem. Biol. (2000) 4:452-460.
56. SPANSWICK D, LEE K: Emerging antiobesity drugs. Expert Opin. Emerg. Drugs (2003) 8:217-237.
57. FAROOQI IS, KEOGH JM, YEO GS et al.: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. (2003) 348:1085-1095.
58. HUSZAR D, LYNCH CA, FAIR-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131-141.
59. VAN DER PLOEG LHT, MARTIN WJ, HOWARD AD et al.: A role for the melanocortin 4 receptor in sexual function. Proc. Nat. Acad. Sci. USA (2002) 99:11381-11386.
60. GANTZ I, FONG TM: The melanocortin system. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E468-E474.
61. LINDBLOM J, KASK A, HAGG E et al.: Chronic infusion of a melanocortin receptor agonist modulates dopamine receptor binding in the rat brain. Pharmacol. Res. (2002) 45:119-124.
62. CABEZA DE VACA S, KIM G, CARR KD: The melanocortin receptor agonist MTII augments the rewarding effect of amphetamine in ad-libitum-fed and food-restricted rats. Psychopharmacology (2002) 161:77-85.
63. SEBHAT I, YE Z, BEDNAREK M et al.: Melanocortin-4 receptor agonists and antagonists: chemistry and potential therapeutic utilities. Ann. Rep. Med. Chem. (2003) 38:31-40.
64. SAILER AW, SANO H, ZENG Z et al.: Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Natl. Acad. Sci. USA (2001) 98:7564-7569.
65. SAITO Y, NOTHACKER HP, WANG Z et al.: Molecular characterization of the melanin-concentrating-hormone receptor. Nature (1999) 400:265-269.
66. SHIMADA M, TRITOS NA, LOWELL BB, FLIER JS, MARATOS-FLIER E: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 396:670-674.
67. MARSH DJ, WEINGARTH DT, NOVI DE et al.: Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA (2002) 99:3240-3245.
68. CHEN Y, HU C, HSU CK et al.: Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology (2002) 143 2469-2477.
69. KOWALSKI TJ, McBRIAR MD: Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs (2004) 13:1113-1122.
70. SHAW WN: Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol. Biochem. Behav. (1993) 46:653-659.
71. GLASS M, BILLINGTON CJ, LEVINE AS: Opioids and food intake: distributed functional neural pathways? Neuropeptides (1999) 33 360-368.
72. STATNICK MA, TINSLEY FC, EASTWOOD BJ et al.: Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284:R1399-R1408.
73. BODNAR RJ: Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides (2004) 25:697-725.
74. DREWNOWSKI A: Metabolic determinants of binge eating. Addictive Behav. (1995) 20:733-745.
75. DE ZWAAN M, MITCHELL JE: Opiate antagonists and eating behaviour in humans: a review. J. Clin. Pharmacol. (1992) 32 1060-1072.
76. KIM S, WAGNER HN, VILLEMAGNE VL et al.: Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J. Nuc. Med. (1997) 38:1726-1731.
77. CHEN RZ, HUANG RR, SHEN CP, MACNEIL DJ, FONG TM: Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. Eur. J. Pharmacol. (2004) 495:63-66.
78. HAWKINS MF, CUBIC B, BAUMEISTER AA, BARTON C: Microinjection of opioid antagonists into the substantia nigra reduces stress-induced eating in rats. Brain Res. (1992) 584:261-265.
79. BRUGMAN S, CLEGG DJ, WOODS SC, SEELEY RJ: Combined blockade of both μ-and κ-opioid receptors prevents the acute orexigenic action of agouti-related protein. Endocrinology (2002) 143 4265-4270.
80. SETOLA V, HUFEISEN SJ, GRANDE-ALLEN KJ et al.: 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. (2003) 63 1223-1229.
81. LEIBEL RL, ROSENBAUM M, HIRSCH J: Changes in energy expenditure resulting from altered body weight. N. Engl. J. Med. (1995) 332:621-628.